Cross-Sector entity
Acadia Pharmaceuticals is most often covered alongside Alkami Technology, which appears in 4 of these 7 stories. The 22-day window averages about 2.2 stories each week. The busiest single day carried 4. pharma accounts for 4 of the 7 tracked stories, while 2 other categories carry the remainder.
7 verified stories tracked
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 14 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Acadia Pharmaceuticals is most often covered alongside Alkami Technology, which appears in 4 of these 7 stories. The 22-day window averages about 2.2 stories each week. The busiest single day carried 4. pharma accounts for 4 of the 7 tracked stories, while 2 other categories carry the remainder. This profile follows 7 Cross-Sector stories mentioning Acadia Pharmaceuticals across the period from February 26, 2026 to March 19, 2026. The tracked stories average 6.7 original sources each. 0% of these stories carry negative sentiment.
Computed from the 7 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Acadia Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Earnings Call
Management hosts a conference call to discuss 2025 performance and 2026 outlook.
Financial Reporting
XOMA files Q4 and Full Year 2025 financial results with the SEC.
Q4 Earnings Call
ACADIA reports strong year-end results and 2026 guidance.
Asset Acquisition
Completion of a significant acquisition of royalty rights from a clinical-stage partner.
Strategic Disclosure
XOMA issues Regulation FD disclosure regarding portfolio updates.
Daybue Stix Launch
Launch of the granule formulation to enhance patient compliance.
Fiscal Milestone
ACADIA reports record quarterly revenue and achieves annual GAAP profitability.
Trial Setback
Phase 3 ADVANCE-2 trial for pimavanserin in schizophrenia fails to meet primary endpoint.
Commercial Launch
Daybue officially enters the U.S. market with strong initial uptake.
FDA Approval
Daybue (trofinetide) approved as the first treatment for Rett syndrome.
Nuplazid Approval
FDA approves Nuplazid for Parkinson's disease psychosis.
XOMA Royalty reported its Q4 and full-year 2025 financial results, highlighting a significant expansion of its royalty portfolio and the continued commercial success of key assets like Vabysmo and Daybue. The company remains focused on its strategic pivot toward becoming a pure-play royalty aggregator in the biotechnology sector.
Source: tickerreport.com · dailypolitical.com
A surge in parental demand for off-label treatments for autism spectrum disorder (ASD) has created a significant rift between families and the medical community. While anecdotal reports drive interest in therapies like GLP-1s and Rett syndrome drugs, physicians cite a lack of robust clinical data and potential safety risks as reasons for their reluctance to prescribe.
Alkami Technology reported strong Q4 2025 results, highlighting a significant shift toward cloud-native digital banking platforms among regional financial institutions. The company's performance, alongside ACADIA Pharmaceuticals' commercial growth, underscores a resilient market for specialized SaaS and high-margin healthcare solutions.
ACADIA Pharmaceuticals and Alkami Technology reported Q4 results that highlight divergent paths for mid-cap growth entities. While ACADIA focuses on the commercial scaling of its rare disease portfolio, Alkami is battling a significant stock correction despite beating revenue expectations.
ACADIA Pharmaceuticals delivered a strong Q4 performance, underscored by the rapid adoption of Daybue and the resilience of its Parkinson’s franchise. The results highlight a successful transition into a diversified commercial-stage biotech with a clear path to sustained profitability.
ACADIA Pharmaceuticals reported a transformative fourth quarter, highlighted by the rapid commercial expansion of Daybue for Rett syndrome and the steady performance of Nuplazid. The company has successfully achieved GAAP profitability, signaling a robust shift toward a diversified rare disease and neurology portfolio.
Source: finance.yahoo.com · finance.yahoo.com
Mid-cap biotech and specialty pharma companies are demonstrating strong commercial maturation, led by record-breaking rare disease revenues and strategic consolidation. Key players like Mirum and Acadia are scaling rapidly, while Alkermes’ acquisition of Avadel signals a shift toward aggressive portfolio expansion in the neuroscience space.
